Literature DB >> 12892721

Anti-cementoblastoma-derived protein antibody partially inhibits mineralization on a cementoblastic cell line.

Marco Antonio Alvarez Pérez1, Sandu Pitaru, Octavio Alvarez Fregoso, José Reyes Gasga, Higinio Arzate.   

Abstract

The effect of human anti-cementoblastoma-derived protein antibody during cementogenesis in vitro was investigated by using human cementoblastoma-derived cells. Cultures treated with 5 microg/ml of CP antibody from day 1 to day 15 revealed a significant decrease in alkaline phosphatase activity (ALP) 40% (p < 0.005), 44% (p < 0.001), 49% (p < 0.1), and 45% (p < 0.02) at 9, 11, 13, and 15 days, respectively. Immunoexpression of osteopontin revealed that in cultures treated with anti-CP antibody, the positive number of cementoblastoma cells was reduced by 87, 83, 69, and 52% at 5, 7, 9, and 11 days, respectively. Bone sialoprotein immunoexpression showed a decrease in positive cells of 82, 51, 60, 80, 83, and 87% at 5, 7, 9, 11, 13, and 15 days, respectively, as compared to controls. The Ca/P ratio of the mineral-like tissue deposited in vitro by cementoblastoma cells revealed that control cultures had a Ca/P ratio of 1.45 and 1.61 at 5 and 15 days, whereas experimental cultures revealed a Ca/P ratio of 0.50 and 0.79 at 5 and 15 days, respectively. Electron diffraction patterns showed inner double rings representing D-spacing that were consistent with those of hydroxyapatite in both control and experimental cultures. Examination of the crystallinity with high resolution transmission electron microscopy showed homogeneous and preferential spatial arrangement of hydroxyapatite crystallites in control and experimental cultures at 15 days. Atomic force microscopy images of control cultures at 5 and 15 days revealed small granular particles and grain agglomeration that favored the formation of crystalline plaques with a lamellar-like pattern of the mineral-like tissue. Experimental cultures at 5 and 15 days showed tiny and homogeneous granular morphology. The agglomerates maintained spherical morphology without organization of needle-like crystals to form plaque-like structures. Based on these findings, it is hypothesized that cementoblastoma-derived protein may be associated to crystal growth, compositional and morphological features during the mineralization process of cementum in vitro.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12892721     DOI: 10.1016/s1047-8477(03)00116-3

Source DB:  PubMed          Journal:  J Struct Biol        ISSN: 1047-8477            Impact factor:   2.867


  5 in total

1.  Multilineage differentiation of dental follicle cells and the roles of Runx2 over-expression in enhancing osteoblast/cementoblast-related gene expression in dental follicle cells.

Authors:  K Pan; Q Sun; J Zhang; S Ge; S Li; Y Zhao; P Yang
Journal:  Cell Prolif       Date:  2010-06       Impact factor: 6.831

2.  Isolation of protein-tyrosine phosphatase-like member-a variant from cementum.

Authors:  A Valdés De Hoyos; L Hoz-Rodríguez; H Arzate; A S Narayanan
Journal:  J Dent Res       Date:  2011-11-07       Impact factor: 6.116

3.  Hypoxia promotes CEMP1 expression and induces cementoblastic differentiation of human dental stem cells in an HIF-1-dependent manner.

Authors:  Hwajung Choi; Hexiu Jin; Jin-Young Kim; Ki-Taek Lim; Han-Wool Choung; Joo-Young Park; Jong Hoon Chung; Pill-Hoon Choung
Journal:  Tissue Eng Part A       Date:  2014-01       Impact factor: 3.845

4.  Controlled release of recombinant human cementum protein 1 from electrospun multiphasic scaffold for cementum regeneration.

Authors:  Xiaofeng Chen; Yu Liu; Leiying Miao; Yangyang Wang; Shuangshuang Ren; Xuebin Yang; Yong Hu; Weibin Sun
Journal:  Int J Nanomedicine       Date:  2016-07-12

5.  Bone regeneration in rat cranium critical-size defects induced by Cementum Protein 1 (CEMP1).

Authors:  Janeth Serrano; Enrique Romo; Mercedes Bermúdez; A Sampath Narayanan; Margarita Zeichner-David; Leticia Santos; Higinio Arzate
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.